Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2536648 | European Journal of Pharmacology | 2006 | 7 Pages |
Abstract
Peripheral-type benzodiazepine receptors have been found throughout the body, and particularly, in high numbers, in neoplastic tissues such as the ovary, liver, colon, breast, prostate and brain cancer. Peripheral-type benzodiazepine receptor expression has been associated with tumor malignity, and its subcellular localization is important to define its function in tumor cells. We investigated the presence of peripheral-type benzodiazepine receptors in Ehrlich tumor cells, and the in vitro effects of peripheral-type benzodiazepine receptors ligands on tumor cell proliferation. Our results demonstrate the presence of peripheral-type benzodiazepine receptor in the nucleus of Ehrlich tumor cells (85.53 ± 12.60%). They also show that diazepam and Ro5-4864 (peripheral-type benzodiazepine receptor agonists) but not clonazepam (a molecule with low affinity for the peripheral-type benzodiazepine receptor) decreased the percentage of tumor cells in G0-G1 phases and increased that of cells in S-G2-M phases. The effects of those agonists were prevented by PK11195 (a peripheral-type benzodiazepine receptor antagonist) that did not produce effects by itself. Altogether, these data suggest that the presence of peripheral-type benzodiazepine receptor within the nucleus of Ehrlich tumor cells is associated with tumor malignity and proliferation capacity.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Mônica Sakai, Evelise Souza Monteiro Fonseca, Silvia Catarina Salgado Oloris, PatrÃcia Matsuzaki, Andréia Hanada Otake, Kátia Ramos Moura Leite, Cristina Oliveira Massoco, Maria Lúcia Zaidan Dagli, João Palermo-Neto,